BofA raised the firm’s price target on Sabra Health Care (SBRA) to $21 from $20 and keeps a Buy rating on the shares. The firm is positive on the company’s decision to remain disciplined on the external growth front, but acknowledges the markets concern that it may fall behind as others shift to an offensive strategy.
Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SBRA: